Henry R, et al. - This study assessed treatment satisfaction with ITCA 650 (continuous exenatide in osmotic mini-pump) versus twice-daily exenatide injections (Ex-BID) in patients with type 2 diabetes (T2D), not adequately controlled by metformin. Researchers observed that meaningfully improved glucose control and significantly increased overall treatment satisfaction was evident as a result of ITCA 650 added to metformin-treated patients with T2D, and those who switched to ITCA 650 from Ex-BID.